文献速递白血病

维奈克拉联合方案对比单用去甲基化药物:PETHEMA登记研究

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.
PubMed 文献 · Leukemia · 2026-10-06

基于PETHEMA登记的真实世界研究,比较不适合强化疗的新诊断AML患者中维奈克拉联合方案与去甲基化药物单药的疗效,纳入2610例患者。联合方案复合完全缓解率更高(64,4% vs 20,0%),30天和60天死亡率更低,中位总生存11,4 vs 8,2个月(HR 0,66)。获益在倾向评分匹配、限定时代分析和多因素回归中均得到确认,并呈现分子学梯度。

要点

  • 不适合强化疗的新诊断AML中,维奈克拉联合方案较单用去甲基化药物提高缓解率并降低早期死亡率
  • TP53突变者生存仍差(7,0 vs 3,7个月),继发于MDS/MPN的AML未见获益

核心结论

  • 在不适合强化疗的新诊断AML真实世界人群中,维奈克拉联合方案较去甲基化药物单药显著改善复合完全缓解率、早期死亡率和总生存。

研究设计与样本

  • PETHEMA登记研究的真实世界比较分析,纳入2610例患者,其中维奈克拉联合方案929例、去甲基化药物单药1681例。

主要发现

  • 倾向评分匹配(HR 0,66)、限定时代分析(HR 0,71)和多因素Cox回归均确认获益。
  • 分子学梯度:IDH2(HR 0,43)、NPM1(0,46)、FLT3-ITD(0,48)、IDH1(0,55)、预后良好核型(0,25);TP53突变者总生存改善(HR 0,70)但仍差(7,0 vs 3,7个月);继发于MDS或MPN的AML未见获益。

临床怎么用

  • 支持在不适合强化疗的新诊断AML中优先考虑维奈克拉联合方案,尤其IDH2、NPM1、FLT3-ITD、IDH1突变及预后良好核型者。

局限性

  • 为真实世界登记研究,非随机对照;既往同类比较受随访短、基因检测率低和统计效能不足限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world comparisons of venetoclax (VEN)-based versus hypomethylating agent (HMA) monotherapy in unfit, newly diagnosed AML remain limited by short follow-up, low genomic testing, and inadequate statistical power. We conducted the largest comparative analysis to date from the PETHEMA registry, including 2610 patients (929 VEN-based, 1681 HMA). Composite complete remission was higher with VEN-based therapy (64.4% vs 20.0%; P < 0.001), and both 30-day (4.8% vs 7.5%; P = 0.011) and 60-day mortality (9.7% vs 15.7%; P < 0.001) were significantly lower. Median overall survival was 11.4 versus 8.2 months (HR, 0.66; 95% CI, 0.60-0.73; P < 0.001), consistent with that of VIALE-A (HR, 0.66) despite a broader cohort (ECOG 3-4, 4.7%; secondary AML, 42.5%; adverse-risk cytogenetics, 36.5%). The benefit was confirmed by propensity score matching (HR, 0.66), era-restricted analysis (HR, 0.71), and multivariable Cox regression. A molecular gradient of benefit emerged-greatest in IDH2 (HR, 0.43), NPM1 (0.46), FLT3-ITD (0.48), IDH1 (0.55), and favorable-risk cytogenetics (0.25). In TP53-mutated AML, OS improved significantly (HR, 0.70) but remained dismal (7.0 vs 3.7 months); no benefit was observed in AML arising from antecedent MDS or MPN. These findings confirm and extend VIALE-A, refining patient selection for VEN-based therapy in routine practice.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Aspas Requena G, Aguiar E, Brioso J, et al. Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry. Leukemia. 2026. PMID: 42839073. doi:10.1038/s41375-026-03154-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。